{
    "clinical_study": {
        "@rank": "139399", 
        "arm_group": [
            {
                "arm_group_label": "TZP-101", 
                "arm_group_type": "Active Comparator", 
                "description": "TZP-101"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "A study to evaluate the safety of TZP-101 in comparison with placebo when administered\n      post-operatively in patients who have undergone partial bowel resection."
        }, 
        "brief_title": "A Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": "Postoperative Ileus", 
        "condition_browse": {
            "mesh_term": "Ileus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient is 18 to 80 years of age, inclusive.\n\n          -  Patient is scheduled to undergo open bowel resection.\n\n          -  Female patients must be postmenopausal (for at least 1 year), surgically sterile,\n             practicing true sexual abstinence, OR must be using adequate contraception (in the\n             opinion of the investigator) for the duration of the study, including the follow-up\n             period (e.g. contraceptive implants, injectables, oral contraceptives, some\n             intrauterine devices [IUD], and/or barrier method (condom or occlusive cap) with\n             spermicidal foam/gel/film/cream/suppository).\n\n          -  Hormonal and IUD methods of contraception must be established for a period of 3\n             months prior to dosing and, if changed, alternative methods should be used as\n             directed by the investigator throughout the duration of the study.\n\n          -  Females of childbearing potential must have a negative pregnancy test at screening\n             and admission\n\n        After surgery and prior to administration of the first dose of study drug, the following\n        eligibility criteria must be assessed:\n\n          -  Patient underwent open bowel resection.\n\n          -  Patient has given written informed consent\n\n        Exclusion Criteria:\n\n          -  Patient weighs more than 200kg (441 pounds).\n\n          -  Patient is classified as American Society of Anesthesiologists (ASA) Class 4, 5, or 6\n\n          -  Patient has complete bowel obstruction.\n\n          -  Patient is scheduled to receive a low rectal or anal anastomosis (e.g. proctectomy or\n             ileoanal anastomosis) (low rectal is defined as below the anterior peritoneal\n             reflection - typically 9-10cm from the anal verge).\n\n          -  Patient is scheduled for laparoscopic or laparoscopic hand-assisted procedure.\n\n          -  Patient's surgical procedure is considered to be an emergency procedure.\n\n          -  Patient has significant impairment of liver or renal function (alanine\n             aminotransferase (ALT)/ aspartate aminotransferase (AST) 2.5 times the upper limit of\n             normal; creatinine clearance <30mL/minute (min), estimated using serum creatinine\n             with the formula [(140 - age in years) \u00d7 weight in kg]/[(72 \u00d7 serum creatinine in\n             mg/dl) \u00d7 0.85 for female patients].\n\n          -  Patient is anticipated to require prolonged post-operative ventilation.\n\n          -  Patient has a psychiatric disorder or cognitive impairment that, in the opinion of\n             the Investigator, would interfere with participation in the study.\n\n          -  Patient has participated in an investigational drug study 30 days prior to the study\n             initiation.\n\n          -  Patient has a positive laboratory test result for controlled substances (other than\n             for those prescribed by a medical professional and/or accounted for by concomitant\n             medications) at screening.\n\n          -  Patient is known to have Hepatitis B or Hepatitis C infection currently associated\n             with clinically significant symptoms or abnormal liver function.\n\n          -  Patient has a recent, adult history of clinically significant hypersensitivity\n             reaction(s) to any drug, in the opinion of the Investigator.\n\n          -  Patient is pregnant (confirmed by pregnancy test) or is breastfeeding.\n\n          -  Patient has known history of drug or alcohol abuse within the previous year.\n\n        After surgery and prior to administration of the first dose of study drug, the following\n        eligibility criteria must be assessed:\n\n          -  Patient received a low rectal or an anal anastomosis (e.g. proctectomy or ileoanal\n             anastomosis) (low rectal is defined as below the anterior peritoneal reflection -\n             typically 9-10cm from the anal verge).\n\n          -  Patient underwent a laparoscopic procedure (including a hand-assisted laparoscopic\n             procedure).\n\n          -  Patient is classified as American Society of Anesthesiologists (ASA) Class 4, 5, or\n             6.\n\n          -  Patients has received ulimorelin previously"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 14, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01710982", 
            "org_study_id": "NPJ5004-04/2011 (SDS)"
        }, 
        "intervention": [
            {
                "arm_group_label": "TZP-101", 
                "intervention_name": "TZP-101", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 17, 2012", 
        "number_of_arms": "2", 
        "official_title": "A Multicentre, Randomised, Double-blind, Placebo-Controlled Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection", 
        "overall_official": {
            "affiliation": "Norgine Ltd", 
            "last_name": "Sandy Eisen, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Romania: National Medicines Agency"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate the safety of TZP-101 in comparison with placebo when administered post-operatively in patients who have undergone partial bowel resection.", 
            "measure": "Number of Participants with Treatment Emergent Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "No", 
            "time_frame": "32 days post-dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01710982"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Norgine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Norgine", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}